CYP2C9 rs1799853: What Your Genotype Means
The rs1799853 variant is a specific genetic change in the CYP2C9 gene that is associated with reduced enzyme activity. This variation can influence how an individual metabolizes certain medications, such as the anticoagulant warfarin and the anticonvulsant phenytoin.
What each genotype means
Normal enzyme activity
This genotype corresponds to the CYP2C9*1/*1 status, which is considered the wild-type or normal metabolizer profile. Individuals with this genotype typically metabolize medications like warfarin and phenytoin at standard rates. Please discuss any medication dosing with your clinician or pharmacist to ensure your treatment plan is appropriate for your health needs.
This is the most common genotype in most populations, representing the standard reference for enzyme activity.
Reduced enzyme activity
This genotype corresponds to the CYP2C9*1/*2 status, which is associated with decreased activity of the CYP2C9 enzyme. Research indicates that carriers may metabolize certain drugs, such as warfarin, more slowly than those with the normal genotype, potentially requiring lower doses to avoid side effects like bleeding. Please consult your healthcare provider or pharmacist to discuss how this genetic information may influence your medication management.
The CYP2C9*2 allele is carried by approximately 12-13% of individuals of European ancestry.
Significantly reduced enzyme activity
This genotype corresponds to the CYP2C9*2/*2 status, which results in a more pronounced reduction in CYP2C9 enzyme function compared to the normal genotype. Individuals with this profile may experience slower clearance of drugs like warfarin, which can increase the risk of adverse effects if standard doses are used. It is important to discuss this result with your clinician or pharmacist, as they may consider dose adjustments based on your specific genetic profile.
This homozygous genotype is relatively rare in the general population compared to the heterozygous state.
Understanding the rs1799853 Variant
The rs1799853 variant, commonly referred to in scientific literature as the CYP2C9*2 allele, is a single nucleotide polymorphism (SNP) located within the CYP2C9 gene. This gene is situated on chromosome 10 and provides instructions for making an enzyme that plays a critical role in the breakdown of many common drugs. When this specific variant is present, it can lead to a change in the structure of the resulting enzyme, which often results in a decrease in its metabolic efficiency. Because the enzyme is less effective at processing certain substances, individuals carrying this variant may clear specific medications from their system more slowly than those without it. This can lead to higher concentrations of the drug in the bloodstream, which is a key consideration for clinicians when determining appropriate starting doses for patients prescribed medications metabolized by this pathway.
The Role of the CYP2C9 Gene
The CYP2C9 gene belongs to the cytochrome P450 family, a group of enzymes primarily responsible for detoxifying and metabolizing a wide array of compounds, including both endogenous substances and exogenous drugs. In the context of pharmacogenomics, CYP2C9 is particularly well-known for its role in metabolizing the S-enantiomer of warfarin, a potent anticoagulant used to prevent blood clots. Because the enzyme's activity level directly dictates how quickly the body processes these drugs, genetic variations like rs1799853 are significant. If an individual has reduced enzyme activity, the drug may remain active in the body for a longer duration. This is why understanding a patient's CYP2C9 status is often part of a broader clinical strategy to optimize drug therapy, minimize the risk of adverse effects, and ensure that therapeutic goals are met safely and effectively.
Research and Clinical Associations
Research has consistently demonstrated that the rs1799853 variant is associated with lower warfarin dose requirements. Studies have shown that individuals carrying this variant may require more time to reach a stable dose and may be at an increased risk of over-anticoagulation or bleeding events if standard doses are used. Beyond warfarin, this variant is also linked to the metabolism of phenytoin, an anticonvulsant, where reduced enzyme activity can increase the risk of toxicity. The evidence for these associations is considered moderate to strong in clinical pharmacogenomics. However, it is important to note that genetic status is only one of many factors—including age, body weight, diet, and other medications—that influence how a person responds to a drug. Clinical guidelines from organizations like the Clinical Pharmacogenetics Implementation Consortium (CPIC) provide frameworks for adjusting doses based on these genetic findings, but these should always be applied by a qualified healthcare professional.
Population Frequency and Distribution
The frequency of the rs1799853 variant varies significantly across different global populations. It is most commonly observed in individuals of European ancestry, where the allele frequency is approximately 12.5%. In contrast, this specific variant is very rare in East Asian populations. Because of these differences in distribution, the clinical relevance of testing for this specific SNP can depend heavily on a patient's ancestral background. While this variant is a primary focus for European-based pharmacogenetic studies, other variants in the CYP2C9 gene, such as *5, *6, *8, and *11, are more prevalent in populations with African ancestry and are also important for predicting drug response. Understanding that genetic diversity influences the prevalence of these variants is essential for the equitable application of pharmacogenomic testing in clinical practice.
Navigating Your Genetic Information
If you have received information about your CYP2C9 genotype, it is important to view it as one piece of a larger clinical puzzle. This information is not a diagnosis and does not dictate your health outcomes on its own. You cannot and should not use this information to make changes to your medication regimen, such as altering your dosage or stopping a drug, without consulting your doctor or pharmacist. These professionals are trained to integrate your genetic data with your medical history, current health status, and other lifestyle factors to make safe, evidence-based decisions. If you are concerned about how your genetics might affect your response to a medication, bring your report to your next appointment. Your healthcare provider can explain what the results mean for your specific treatment plan and determine if any adjustments are necessary to ensure your safety and the effectiveness of your therapy.
How common is this variant?
The rs1799853 variant is common in European populations, with an allele frequency of approximately 12.5%, but it is very rare in East Asian populations.
Frequently asked questions
Does having the rs1799853 variant mean I cannot take warfarin?
No, having this variant does not mean you cannot take warfarin. It simply means your body may process the medication differently, and your doctor may need to adjust your starting dose to ensure you reach the correct therapeutic level safely.
Should I get tested for CYP2C9 variants?
Pharmacogenetic testing is not routinely recommended for everyone. You should discuss with your doctor whether testing is appropriate for you based on the specific medications you are taking or may need to take in the future.
Is rs1799853 the only variant that affects warfarin metabolism?
No, warfarin metabolism is complex and influenced by several genes, including VKORC1 and other variants within the CYP2C9 gene. Clinicians often look at a combination of genetic and non-genetic factors to determine the best dose.
Can I change my warfarin dose based on my genetic report?
Absolutely not. Never change your medication dosage based on a genetic report without consulting your healthcare provider. Only a doctor or pharmacist can safely interpret these results in the context of your overall health.
Sources & further reading
Educational information only, last refreshed 10/5/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1799852?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CYP2C9
This rare variant results in a V to L or V to M amino acid substitution in the CYP2C9 enzyme, which is critical for drug metabolism.
Coding variant conferring the CYP2C9*4 allele with decreased enzymatic activity affecting clearance of drugs such as warfarin and phenytoin.
Missense mutation defining the CYP2C9*5 allele that dramatically lowers metabolic activity towards oral anticoagulants and anti-epileptic medications.
A rare variant in the CYP2C9 gene that may impact the metabolism of various clinical drugs.
Defining the CYP2C9*3 (p.Ile359Leu) allele, this variant markedly decreases enzymatic activity, requiring reduced dosages for warfarin and phenytoin to prevent toxicity.
The CYP2C9*2 variant results in reduced enzymatic activity, which is a critical factor in determining appropriate dosing for warfarin and other substrates.